- Published
- 24 April 2021
- Journal article
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study
- Authors
-
Li, Xue ;
- Source
- Journal of Hepatology
Abstract
This multicentre study showed that COVID-19 vaccination appears to be safe and effective in patients with fatty liver.
Rights
This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.
Cite as
Wang, J., Hou, Z., Liu, J., Gu, Y., Wu, Y., Chen, Z., Ji, J., Diao, S., Qiu, Y., Zou, S., Zhang, A., Zhang, N., Wang, F., Li, X., Wang, Y., Liu, X., Lv, C., Chen, S., Liu, D., Ji, X., Liu, C., Ren, T., Sun, J., Zhao, Z., Wu, F., Li, F., Wang, R., Yan, Y., Zhang, S., Ge, G., Shao, J., Yang, S., Liu, C., Huang, Y., Xu, D., Li, X., Ai, J., He, Q., Zheng, M., Zhang, L., Xie, Q., Rockey, D., Fallowfield, J., Zhang, W. & Qi, X. 2021, 'Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.04.026